UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2021
 
Commission File Number: 001-39530
 
ImmunoPrecise Antibodies Ltd.
(Translation of registrant’s name into English)
 
3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☐ Form 40-F  ☒
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 
 

 
EXHIBIT INDEX

Exhibit No.
 
Description
 


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
IMMUNOPRECISE ANTIBODIES LTD.
 
 
 
 
Date: March 17, 2021
 
By:
/s/ Lisa Helbling
 
 
 
Lisa Helbling
 
 
 
Chief Financial Officer
 

ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ImmunoPrecise Antibodies Charts.
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ImmunoPrecise Antibodies Charts.